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Abstract: Progressive lung tissue destruction in lymphangioleiomyomatosis (LAM) occurs as a result of exces-
sive proliferation of LAM cells caused by a mutation in one of the tuberous sclerosis complex suppressor genes,
TSC1 or TSC2. These cells show constitutive activation of the mammalian target of rapamycin (mTOR) path-
way and many of the mTOR-related kinases such as Akt, Erk, S6K1 and S6. Phenotype of LAM cells differs
considerably depending on their microenvironment. LAM cells show differences in morphology, size and ex-
pression of various factors depending on their location in the tumor or body fluids. The presence of LAM cells
in blood, urine, bronchoalveolar lavage fluid (BALF), and chyle proves their ability to metastasis. Antigens of
smooth muscle cells are expressed in most LAM cells. Some of these cells are immunoreactive with HMB-45
antibody, which is used for the immunohistochemical diagnosis of LAM. Receptors for estrogen and progester-
one may also be expressed in these cells, which probably is associated with the fact that LAM occurs almost
exclusively in women of childbearing age. LAM cells via increased production of metalloproteinases are in-
volved in the destruction of the extracellular matrix, as well as the remodeling and damage of lung tissue. Spo-
radic LAM occurs extremely rarely. Therefore a good experimental model of this disease is necessary. To date,
several animal and human cell lines, which both genetically and phenotypically resemble LAM cells, have been
obtained. These cell lines, derived from LAM nodule or an angiomyolipoma, are usually characterized by
a mutation of the TSC2 gene, expression of smooth muscle cell antigens such as a-smooth muscle actin (aSMA)
or S6K1 and S6 protein hyperphosphorylation. Presently, there is no commercially available cell line represent-
ing a good model of LAM. A better understanding of LAM cell biology is necessary for creating a useful model
in vitro for further exploration of both LAM pathomechanisms and more general mechanisms of carcinogenesis.
(Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 1, 1–10)
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Abbreviations
4E-BP1 — eukaryotic translation initiation factor
4E-binding protein 1; AKT — protein kinase B; BALF
— bronchoalveolar lavage fluid; EGF — epidermal
growth factor; EGFR — epidermal growth factor re-
ceptor; elF4E — eukaryotic initiation factor-like pro-
tein; EMMPRIN — extracellular matrix metallopro-
teinase inducer; ER — estrogen receptor; ERK —
extracellular signal-regulated kinase; HIF-1a — hy-
poxia-inducible factor 1a; IGF-1 — insulin-like growth
factor 1; LAM — lymphangioleiomyomatosis; LOH
— loss of heterozygosity; MAPK — mitogen-activat-
ed protein kinase; MART-1 — melanoma-associated
antigen recognized by T cells; MEFs — mouse em-
bryo fibroblasts; MMPs — matrix metalloproteinas-
es; mTOR — mammalian target of rapamycin; PAI-1
— plasminogen activation inhibitor; PDK1 — phos-
phoinositide-dependent kinase-1; PGE2 — endoge-
nous prostaglandin E2; PgR — progesterone recep-
tor; PI3K — phosphoinositide 3-kinase; PLG — plas-
minogen; Rheb — Ras homolog enriched in brain;
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Figure 1. Surgical biopsy from 42-year-old woman with sporadic LAM (hematoxylin-eosin). (A) Lung tissue with thin
walled cyst filled with LAM cells (arrows). (B) LAM nodule with spindle-shaped cells (arrows) in the central part of lesion
and epithelioid-like cells at periphery of nodule (arrowhead)
RhoA — Ras homolog gene family, member A; S6K1
— ribosomal protein S6 kinase beta-1; SRF — serum
response factor; STAT3 — signal transducer and ac-
tivator of transcription 3; TIMPs — tissue inhibitors
of matrix metalloproteinases; TORC1 — target of
rapamycin complex 1; TORC2 — target of rapamy-
cin complex 2; TRP — tyrosinase-related proteins;
TSC — Tuberous Sclerosis Complex; uPA — uroki-
nase-type plasminogen activator; aSMA — smooth
muscle actin
Introduction
Sporadic pulmonary lymphangioleiomyomatosis
(LAM) is a rare disease, affecting almost exclusively
women. It is characterized by intense proliferation of
smooth muscle-like cells (LAM cells) in the lungs and
around bronchi, blood and lymphatic vessels, which
leads to the formation of thin-walled cysts (Figure 1A),
the degeneration and remodeling of lung tissue, pro-
gressive deterioration of lung function and eventual-
ly to death [1–3]. The incidence of sporadic LAM is
estimated at 2.6 per 1 million women. LAM may also
be associated with an autosomal dominant disease
tuberous sclerosis complex (TSC) and occurs in ap-
proximately one-third of the women affected by TSC
[3]. Hamartoma tumors in various organs such as skin,
eyes, kidneys, lungs, and the central nervous system
are present in TSC. Sporadic LAM may also give ex-
trapulmonary symptoms, similar to those in TSC, such
as renal angiomyolipomas, axial lymphadenopathy,
and abdominal lymphangiomyomas [1]. LAM lesions
are characterized by an infiltration and accumulation
of smooth muscle-like cells. Mutations in either tumor
suppressor gene TSC1 or TSC2 cause excessive prolif-
eration of LAM cells and support their ability to me-
tastasis. The phenotype of LAM cells, which include
smooth muscle cells appearance with melanoma phe-
notype is a useful feature in LAM diagnosis [4].
The genetics of LAM and the mTOR pathway
TSC1 and TSC2 belong to the group of tumor sup-
pressor genes, namely the tuberous sclerosis complex.
The TSC1 gene is located on chromosome 9q34, and
consists of 21 exons encoding 1164 amino acid pro-
tein hamartin. The TSC2 gene on chromosome 16p13
contains 41 exons encoding 1807 amino acid protein
tuberin [5]. Hamartin and tuberin form a protein com-
plex, which reduces the level of Rheb-GTP through
activation of GTP-ase, resulting in an inhibitory ef-
fect on mammalian target of rapamycin (mTOR),
a highly conserved serine-threonine kinase that plays
an important role in the regulation of cell growth and
proliferation. Growth factors, phosphoinositide 3-ki-
nase (PI3K) and phosphoinositidedependent kinase-
1 (PDK1) dependent stimulation leads to the phos-
phorylation and activation of protein kinase B (Akt).
Activated Akt, as well as extracellular signal-regulat-
ed kinase (ERK), phosphorylates TSC2 resulting in
inhibition of its activity as a GTP-ase. Akt is known as
an activator of mTOR and is involved in the patho-
genesis of many cancer types. Mutation in one of the
TSC genes causes the protein complex to be inacti-
vated which promotes mTOR activation leading to
the phosphorylation and activation of ribosomal pro-
tein S6 kinase beta-1 (S6K1) and S6 ribosomal sub-
unit. This results in the activation of translational
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mechanisms, increased cell growth and proliferation
(Figure 2) [6]. Active mTOR kinase phosphorylates
eukaryotic translation initiation factor 4Ebinding pro-
tein 1 (4E-BP1) which inhibits its interaction with eu-
karyotic initiation factor-like protein (elF4E), result-
ing in the activation of translation and increased cell
cycling (Figure 2) [7]. mTOR kinase is a component
of two functional complexes: TORC1 and TORC2.
TORC1 is the rapamycin-sensitive mTOR complex
responsible for the regulation of protein translation
initiation and efficiency [8]. Clinical trials with rapa-
mycin as a therapeutic solution for lymphangioleiomy-
omatosis are in an advanced phase [9]. Rapamycin is
a macrolide antibiotic isolated from a strain of Strep-
tomyces higroscopicus. It has been already used as an
immunosuppressive agent. Rapamycin binds to the
cytosolic protein FKPB-12 thereby inactivating the
mTOR kinase. Treatment with rapamycin resulted in
the reduction of tumor volume and improved lung
function in LAM patients [9–11]. However, rapamy-
cin only partially inhibits cell growth, proliferation and
disease progression. Yu et al.[8] presented two possi-
ble explanations of this fact which may coexist in hu-
man LAM. If rapamycin can cause a decrease of cell
size and TORC1 inactivation, then a further decrease
of tumor size could be obtained, for example, via the
inhibition of TSC2-dependent TORC1/rapamycin in-
dependent pathway. The second hypothesis assumes
that rapamycin can cause a decrease in cell number
but some group of cells can still show the TORC1
activation caused by unequal drug delivery or devel-
opment of rapamycin-resistance. It is hoped that tu-
mor size could be further decreased by using other
TORC1 inhibitors, developing a better system of drug
delivery or overcoming rapamycin resistance [8].
LAM in women with TSC is associated with germline
mutations in TSC1 or TSC2 genes. Depending on the
type of TSC gene mutation differences in the inci-
dence and severity of pulmonary symptoms have been
observed. A significantly higher number of cysts in
the lungs was detected in patients with mutations in
the TSC2 gene compared to patients with TSC1 mu-
tations [12]. It seems that, in particular, changes in
the C-terminal segment of tuberin caused by muta-
tions in exons 40–41 of the TSC2 gene may be associ-
ated with LAM symptoms in patients with tuberous
sclerosis [5]. Loss of heterozygosity (LOH) of one of
the TSC genes in somatic cells and clonal expansion
of these cells are responsible for sporadic LAM
[13,14]. According to the „two hits” Knudson’s theo-
ry two independent events lead to the loss of both
functional copies of this gene [15]. Sporadic LAM is
caused by mutations almost exclusively within the
TSC2 gene. Germline mutations were not observed
[16]. There is a significant association between loss
of TSC1/TSC2 function and an increase of LAM cells
invasiveness and motility. Ras homolog gene family,
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Figure 2. Schematic representation of mTOR signaling
pathway. TSC1-TSC2 complex is involved in mTOR inhibi-
tion. Inactivation of this complex in LAM results in constitu-
tive activation of mTOR and in an increase of LAM cells
growth and proliferation. The mTOR may be also activated
by PI3K — dependent activation of Akt leading to the
inhibition of TSC complex. Phosphorylation of TSC2 by
ERK leads to the inactivation of TSC complex. Activation of
mTOR results phosphorylation and activation such proteins
as S6K1 and RhoA leading to enhancement of translation,
cells growth and proliferation as well as cells survival.
Phosphorylation of 4E-BP1 by mTOR leads to inhibition of
interaction between 4E-BP1 and elF4E resulting in activa-
tion of translation and increase in cells proliferation.
Rapamycin, a novel therapeutic solution in lymphangioleio-
myomatosis, is a natural inhibitor of mTOR kinase. mTOR
— mammalian target of rapamycin; TSC — tuberous
sclerosis complex; PI3K — phosphoinositide 3-kinase;
Akt — protein kinase B; ERK — extracellular signal-
regulated kinase; S6K1 — vRibosomal protein S6 kinase
beta-1; RhoA — Ras homolog gene family, member A;
4E-BP1 — eukaryotic translation initiation factor 4E-binding
protein 1; elF4E — eukaryotic initiation factor like protein.
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member A (RhoA) is a small GTPase protein known
to regulate the actin cytoskeleton in the formation of
stress fibers. RhoA activity is regulated by TSC1/TSC2
complex formation. TSC2 binds the TSC1 via its bind-
ing domain, which overlaps with the RhoA activating
domain present in the protein encoded by the TSC1.
TSC2 mutation results in the abnormal formation of
the TSC1/TSC2 complex and an increase in RhoA
activity which increases the invasiveness and migra-
tion ability of LAM cells [17]. It was shown that trans-
fection of primary culture of human LAM cells by
normal gene TSC2, as well as TSC1 gene silencing
resulted in the inhibition of excessive RhoA activity.
Loss of TSC2 function by the dysregulation of the
TSC1/TSC2 complex formation leads to the TSC1-
dependent RhoA activation, an increase of invasive-
ness, migration, and thus the metastatic nature of
LAM cells [17]. The ability to metastasis of TSC2–/–
cells can be also explained by the presence of cleaved
forms of b-catenin leading to an increased matrix
Figure 3. Surgical biopsy from 42-year-old woman with sporadic LAM (immunohistochemical staining). (A) a-smooth
muscle actin, a-SMA; (B) HMB-45; (C) Estrogen receptor, ER, (D) Progesterone receptor, PgR
metalloproteinase 7 (MMP7) expression and thus the
invasiveness of these cells [18].
LAM cell phenotype
LAM cells are morphologically heterogeneous with
a phenotype ranging from smaller spindle-shaped
smooth muscle-like cells to larger epithelioid-like cells
which are abundant with the cytoplasm. Smaller, spin-
dle-shaped cells are located centrally, while epithe-
lioid-like cells are observed mainly at the periphery
of the LAM nodule (Figure 1B) [2, 19, 20]. The ar-
rangement of these cells becomes more irregular as
the disease progresses [20]. It was suggested that LAM
cells proliferation occurs in the central part of the
tumor, and then the cells grow intensively, differenti-
ate and migrate to peripheral parts of the tumor [20].
LAM cells show phenotypic features of smooth
muscle cells since they express smooth muscle actin
(aSMA) (Figure 3A), vimentin and desmin [2, 11, 20,
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21]. Ultrastructural studies showed the presence of
filaments that react with antibody to smooth muscle
F-actin, as well as intermediate desmin and vimentin
filaments which were located around nuclei [20]. Ex-
pression of antigens specific to melanoma, and espe-
cially the reaction with the HMB-45 antibody (Fig-
ure 3B) is a useful tool for lymphangioleiomyomato-
sis diagnosis by immunohistochemistry [11, 20]. HMB-
45 is a mouse monoclonal antibody which reacts with
gp100 glycoprotein, a product of alternative splicing
of pmel17, characteristic for melanoma and LAM
cells, especially for epithelioid-like cells of the latter
[20]. Electron-dense granules resembling immature
melanosomes in LAM cell cytoplasm were observed
by electron microscopy. Further studies confirmed the
immunoreactivity of these structures with the HMB-
45 antibody [22]. Some of the LAM cells also express
a small transmembrane protein, melanoma-associat-
ed antigen recognized by T cells (MART-1), which is
widely expressed in melanoma cells [23]. Both gp100
and MART-1 can be recognized by T cells, increasing
the susceptibility of these cells to the cytotoxic activ-
ity of T cells. This feature may become an important
therapeutic target. Expression of tyrosinase-related
proteins TRP-1 (gp-75) and TRP-2 was also observed
in LAM cells [23]. Other markers of melanoma, such
as CD63, a protein belonging to the tetraspanin fam-
ily, or a recently described unknown protein which
reacts with PNL2 antibody, are also present in LAM
cells [24].
Due to the fact that LAM almost exclusively af-
fects women, estrogen (ER) and progesterone (PgR)
receptors were examined in LAM cells. The expres-
sion of both receptor types was observed in the nu-
clei of LAM cells (Figure 3 C, D). However, greater
frequency and stronger reactivity was seen for PgR
compared to ER [25, 26]. The expression of both re-
ceptors was observed mainly in larger epithelioid
LAM cells and in some relatively larger spindle
shaped cells [26]. Estrogen treatment of TSC2-null
ELT3 (epithelioid leiomyoma tumor) cells led to in-
creased cell proliferation in vitro and significantly
enhanced the metastazing ability of these cells in vivo
[27]. Although the first therapeutic trials were based
on suppression of estrogen activity, the efficacy of
these therapies has not yet been proven. Migration
and behavior of LAM cells depends on the activities
of specific chemokines. These cells, like other cancer
cells, have a characteristic expression profile of
chemokines and their receptors. High expression of
CXCR4 receptor was detected in LAM cells. Loss of
TSC2 function, through activation of mTOR, can lead
to the increased expression of hypoxia-inducible fac-
tor (HIF-1a), which is a transcriptional factor for sev-
eral genes during hypoxia, including CXCR4. The
expression of some chemokines and their receptors
may be partially regulated by hypoxia occurring in
patients with moderate or highly advanced LAM.
LAM cells also produce large amounts of CCL2.
CCL2 and its receptors CCR2 and CCR10 probably
play an important role in the pathogenesis of LAM.
In vitro studies showed that in a heterogeneous pop-
ulation of cells CCL2 was a selective chemoattracta-
nt of LAM cells [28]. Interestingly, high expression
of this chemokine was also observed in a dominant
negative transgenic mouse model of TSC2 [28]. High
expression of the chemokines CCL2, CXCL1 and
CXCL5 in bronchoalveolar lavage fluid (BALF) of
LAM patients as well as in cells derived from LAM
nodules was observed. This may suggest their involve-
ment in the pathogenesis of LAM [28]. Clements et
al. [29] showed CCR3, CXCR4, CXCR6 and
CXC3CR1 expression in angiomyolipoma and LAM.
Ligands for these receptors (CXCL12 CX3CL1,
CCL11, CCL24, and CCL28) are responsible for the
phosphorylation of Akt and mitogen-activated pro-
tein kinase (MAPK), which promote the mTOR path-
way. Interestingly, CXCL12, the only known ligand
for CXCR4, was produced by type II pneumocytes
surrounding the LAM nodules and vascular endot-
helium [29]. It may function as a chemoattractant and
survival factor for circulating LAM cells. CCR1,
CCR7, and CXCR7 mRNA were detected in angi-
omyolipoma primary cell culture [29]. Expression of
the specific chemokine profile in LAM was shown to
affect LAM cells migration, metastasis, tumor pro-
gression and interaction between LAM and stroma
cells [28–30].
The ability to metastasis of LAM cells is also re-
lated to the production of proteolytic enzymes, for
example, matrix metalloproteinases (MMPs). LAM
cells showed expression of several metalloproteinas-
es such as MMP-1, MMP-2, MMP-3, MMP-7, and
MMP-9 [30]. Proteolysis of extracellular matrix com-
ponents, including different types of collagen, pro-
teoglycans and elastic fibers is regulated by the activ-
ity of MMPs and their tissue inhibitors (TIMPs).
Hayashi et al. [31] demonstrated immunohistochem-
ically the expression of MMP-1, MMP-2 and MMP-9
in LAM cells. An interesting finding was that mor-
phologically different types of cells in the LAM nod-
ule showed a different expression pattern of MMPs.
Large LAM cells that were immunoreactive with the
HMB-45 antibody showed a stronger reaction with
MMP-2 and MMP-9 than other types of LAM cells in
the nodule [31]. Elevated levels of Serum Response
Factor (SRF) in LAM cells may be an important fac-
tor in the degradation of lung tissue. SRF is an essen-
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tial transcriptional factor which is highly expressed in
developing smooth muscle cells, however, its expres-
sion decreases in mature cells [32]. LAM cells are
morphologically similar to immature myoblasts and
expression of SRF was observed in both nuclei and
cytoplasm. High SRF level increased expression of
MMP-2 and MMP-14 and reduced expression of one
of their inhibitors, the metalloproteinase inhibitor 3
(TIMP-3) [32]. The lower level of TIMP-3 may be of
particular significance in the progression of LAM
since TIMP-3-null mice showed a destructive lung
phenotype, which led to progressive emphysema and
a shorter life span [32]. A study with the overexpres-
sion of MMPs in human lung fibroblasts demonstrat-
ed that high levels of SRF may also regulate the plas-
minogen system in vitro [33]. SRF, by increasing lev-
els of urokinase-type Plasminogen Activator (uPA),
activates plasminogen (PLG) to plasmin, which in turn
activates MMPs. A high level of SRF reduces the ex-
pression of plasminogen activation inhibitor (PAI-1).
These results [33] were confirmed by laser micro-dis-
section, RT-PCR, and immunohistochemistry on sec-
tions of lung tissue from LAM patients. Strong posi-
tive immunohistochemical reactions with uPA and
PLG were observed in LAM nodules compared to
the surrounding healthy lung tissue. PAI-1 expression
was observed in normal lung tissue, whereas it was
not present in LAM lesions [33]. Another protein
which was shown to regulate the activity of MMPs,
extracellular matrix metalloproteinase inducer (EM-
MPRIN/CD147), was detected in LAM cells. Dou-
ble immunofluorescence revealed co-localization of
EMMPRIN/CD147 and aSMA, MMP-2 or MMP-9.
Levels of EMMPRIN/CD147 were significantly ele-
vated in LAM lesions and BALF of LAM patients
[34]. High expression of MMPs in TSC2–/– angiomyo-
lipoma cells seems to be independent of mTOR ki-
nase and their levels do not change following rapam-
ycin treatment, therefore the treatment of LAM by
this mTOR inhibitor may have limited clinical effec-
tiveness [35]. It has been hypothesized that doxycy-
cline, as an inhibitor of MMPs, could inhibit degra-
dation of lung tissue in LAM patients. Clinical trials
have shown that administration of doxycycline to
LAM patients resulted in lower levels of MMP-2,
MMP-9 in serum and urine, decreased symptoms and
improved life quality [36, 37]. However, in vitro stud-
ies showed that there was no significant reduction in
the level and activity of MMPs in the ELT3–/– cells,
derived from an animal model of LAM, the Eker rat,
after doxycycline cells treatment [38]. Thus, the effi-
cacy of doxycycline to inhibit MMPs activity in LAM
patients needs to be further investigated.
Many of the above described features of LAM cells
reveal their ability to metastasize. So far, the most
useful marker of these cells, commonly used in the
differential diagnosis of LAM is an immunohis-
tochemical reaction with the antibody HMB-45. Ex-
ploring the biology of LAM cells, in particular char-
acterization of disseminated neoplastic LAM cells in
the body fluids, could lead to a development of new
diagnostic tools which would be less invasive than
a biopsy. In order to find specific markers for LAM
cells circulating in blood, urine or BALF, Pacheco-
Rodriguez et al. [39] carried out a series of molecular
studies. Analysis of blood samples from LAM patients
showed that cells with TSC2 LOH were immunore-
active with anti-CD235a antibody against glycophor-
in-A, a sialoglicoprotein present in erythrocyte’s cell
membrane. The expression of this protein was also
demonstrated in 31% of lung LAM cases. This pro-
tein was also reported to be present on the surface of
breast cancer and melanoma cells [39]. It was also
found that cells from the nodule express CD44v6, the
product of CD44 alternative splicing [40]. CD44 is
a class I transmembrane glycoprotein. The formation
of CD44 isoforms is regulated by a signaling pathway
involving the Ras-mitogen activated protein kinase
pathway [40]. Isoforms generated by alternative splic-
ing of 10 additional exons from v1 to v10 resulted in
an insertion of additional segments in the extracellu-
lar domain of the protein. The extracellular domain
of CD44 binds metalloproteinases such as MMP-7 and
MMP-9, which cleave CD44 and CD44v6 [40].
CD44v6 is associated with carcinogenicity and is in-
volved in homing during metastasis, and its expres-
sion was demonstrated on squamous cell carcinoma
and adenocarcinoma cells [40]. The CD44v6 domain
can also bind Fas ligand, which inhibits apoptosis.
LAM lesions showed moderate reaction with CD44,
however, the usefulness of this antigen for LAM cells
isolation from body fluids is limited because it shows
a strong immunoreactivity with other cell types such
as vascular smooth muscles cells, bronchial epithelial
cells and hyperplastic type II pneumocytes [40].
A large percentage of cells in the LAM nodule showed
expression of CD44v6 in contrast to other cells in the
lung tissue. CD44+/CD44v6+ cells from LAM nod-
ule, exhibit LOH of the TSC2 gene [40]. The pres-
ence of CD44v6 was found on LAM cells isolated
from BALF, urine, and chyle [41]. Microarray analy-
sis performed on material derived from the skin tu-
mor associated with TSC showed high expression of
CD9, a protein of the tetraspanin family which plays
an important role in cell morphology, motility, inva-
siveness, adhesion as well as cellular interactions [41].
Its expression may correlate with metastases of tu-
mor cells. A higher level of CD9 was correlated with
TSC2 LOH [41]. Both CD44v6 and CD9 are useful
markers to distinguish and isolate LAM cells from
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Table 1. Mechanisms of metastasis in lymphangioleiomyomatosis
Mutations and markers in LAM cells Mechanisms
Loss of heterozygosity of TSC2 Constitutive activation of mTOR pathway, enhanced cell growth and proliferation,
cells survival [13, 14]
Estrogen receptor, ER Estrogens promote proliferation, survival and lung colonization of ELT3 cells,
activation of MMPs [27]
Chemokines and its receptors e.g. Enhanced migration, homing, and interactions between LAM and stroma cells [28–30]
CCL2, CCR2, CXCR4
Metalloproteinases, MMPs e.g. Degradation of extracellular matrix which facilitates LAM cells invasion [27]
MMP-2, MMP-9
CD44, CD44v6 Homing, inhibition of apoptosis by binding Fas ligand [40]
CD9 Motility, invasiveness, adhesion, cells interactions [41]
body fluids. CD44v6+/CD9+ cells showed TSC2
LOH in 80% in BALF, 69% in urine and 50% in chyle
[41]. Changes in metastatic cell phenotype can occur
depending on the microenvironment. The LAM cells
in different locations may exhibit different antigen
expression patterns such as CD44/CD44v6 expression
in LAM cells from the LAM nodule, CD235 in LAM
cells in blood and CD44v6/CD9 expression in LAM
cells in urine, BALF, and chyle [41].
Metastatic features of LAM cells are presented in
Table 1.
Cell lines as a model of LAM
Lymphangioleiomyomatosis is a rare interstitial lung
disease. An applicable experimental model is still re-
quired for carrying out further studies. The most pop-
ular animal model of LAM is the Eker rat with TSC2
germline mutation occurring in one of its alleles. In
this model rats develop renal adenomas, uterine lei-
omyomas and pituitary adenomas. In some of them
loss of heterozygosity for the TSC2 gene may be ob-
served. Heterozygous TSC2+/– mice develop changes
similar to those observed in the Eker rat, and some of
them were characterized by TSC2 LOH. In TSC1+/–
mice a similar phenotype was seen, however, kidney
tumors developed with a lower frequency [42]. Ger-
mline inactivation of both alleles of TSC1 or TSC2 in
mice is lethal [43].
The most commonly used cell lines derived from
an animal model of LAM are TSC2-null lines derived
from tumors present in the Eker rat, ELT 3, 4, 6, 9,
10. These lines, isolated from uterine leiomyomas,
exhibit expression of smooth muscle antigens and
constitutive activation of mTOR kinase. All of these
cell lines express receptors for estrogen and progest-
erone, however, only ELT6 was shown to respond to
these hormones in culture [44]. Although TSC1 and
TSC2 knockouts are lethal, a cell line derived from
embryonic TSC2-null Eker rat, named EEF-8, was
obtained, as well as TSC2–/– fibroblasts derived from
this model [45]. Mouse embryo fibroblasts (MEFs)
isolated from both the TSC1 and TSC2 knockout mice
exhibited constitutive activation of mTOR and S6K1
phosphorylation [46, 47].
In 2001, Arbiser et al. [48] generated a cell line
from human sporadic angiomyolipoma of a 63-yearold
patient which was not associated with TSC. Cells were
transfected with SV40 large T antigen and human
telomerase to obtain a stable and immortalized cell
line. This cell line expressed tuberin and hamartin,
however, it developed an increased activation of
MAPK. There was a positive immunohistochemical
reaction with cytokeratins which suggests that this
culture can represent epithelioid-like cells. This cell
line is commercially available [48].
Human cell lines were successfully isolated from
tissue obtained from patients with angiomyolipoma
in Tuberous Sclerosis Complex. Lesma et al. [49] char-
acterized two cell lines derived from angiomyolipo-
ma of a 42-year-old patient with TSC. Cells were char-
acterized by immunocytochemistry showing high ex-
pression of aSMA and HMB-45 antibody immunore-
activity. However, staining with S100, vimentin, CD68
and keratins 8/18 was negative. The second cell pop-
ulation, epithelial-like cells, strongly reacted with the
antibody against cytokeratins 8/18 and HMB-45 and
did not express a-SMA, S-100, vimentin or CD68.
Epithelial-like cells (R+) strongly reacted with Rho-
A antibody but did not show LOH for the TSC2 gene
[49]. Smooth muscle-like cells (A+) revealed TSC2
LOH and a lack of tuberin expression. A+ cells had
receptors for epidermal growth factor (EGF) and in-
sulin-like growth factor 1 (IGF-1) on their surface and
EGF medium supplementation was essential for the
survival and proliferation of these cells in culture [49].
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These cell lines were used to study the effects of mon-
oclonal antibody anti-EGFR, rapamycin and other
mTOR pathway blockers on cell survival. It was found
that anti-EGFR antibody effectively inhibited the
proliferation of these cells suggesting its use as an
effective therapeutic option [50]. A study of the role
of survivin as an inhibitor of apoptosis in these cell
lines showed that it may be an important anti-apop-
totic and survival factor with the potential of becom-
ing the target of future therapies [51]. Clements et al.
[52] demonstrated two cell line populations derived
from angiomyolipoma: spindle-shaped cells and epi-
thelioid-like cells. The cultured cells showed consti-
tutive activation of S6K1 protein and strong expres-
sion of aSMA. mRNA of gp100, and MART-1 (spin-
dle- shaped cells) and estrogen receptors was detect-
ed in these cells by RT-PCR. Cells were cultured in
the presence of epidermal growth factor [52] and used
to study the role of chemokines in LAM and angi-
omyolipoma [29] as well as the effects of doxycycline
on the proliferation, production of MMPs and adhe-
sion of LAM-related cells [38]. Yu et al. [53] described
a line derived from human angiomyolipoma. The cells
were spindle-shaped, showed LOH for TSC2, the ex-
pression of estrogen receptors and hiperphosphory-
lation of S6. Both estradiol and, unexpectedly, tamox-
ifen, stimulated their growth demonstrating that
tamoxifen may act as an estrogen agonist in human
cultured angiomyolipoma cells [53], in opposition to
being an estrogen antagonist in Eker rat-derived ELT3
cells [54]. All human angiomyolipoma cells were used
between the second and fourth passage in this exper-
iment [53]. The same, but immortalized human angi-
omyolipoma cell line, was used to study the level of
MMP-2 expression and the mechanism leading to its
overexpression [35].
Black et al. [55] studied LAM cells isolated from
a fragment of lung tissue using laser micro-dissection.
They were immunohistochemically characterized as
HMB-45 positive. All cells in this experiment were used
between the fourth and eighth passage. The authors
found reduced expression of endogenous prostaglan-
din  E2 (PGE2) associated with the decreased expres-
sion of the cyclooxygenase 2 (COX2). Production of
the VEGF protein family by these cells was document-
ed [55]. Goncharova et al. [56] obtained LAM cell lines
from the LAM nodule of lung tissue derived from pa-
tients after lung transplantation. Lines were charac-
terized as a-SMA positive, and HMB-45 negative.
These cells showed constitutive hyperphosphorylation
of p70S6, S6 protein and high proliferative activity, even
without growth factor supplementation. Cells were
used between the 3rd and 12th passage. This study
showed that TSC2 dysfunction and constitutive acti-
vation of mTOR/S6K1 attenuates growthinhibitory
effect of IFN-b and suggests that combination of rapa-
mycin and IFN-b cells treatment could abrogate LAM
cells proliferation [56]. The same authors have next
demonstrated that activation of signal transducer and
activator of transcription 3 (STAT3) was essential for
the proliferation and survival of this cell line [57].
Conclusions
LAM cells are a heterogeneous population of cells.
Their proliferation leads to the formation of LAM
lesions, cysts and lung tissue destruction. Differences
in size, morphology and antigen pattern expression,
make the identification and isolation of LAM cells
very difficult. The phenotype of these cells depends
on their microenvironment, exposure to cytokines,
growth factors and interactions with other cells.
A better understanding of the nature of LAM cells is
necessary in order to find an applicable in vitro mod-
el, as well as new therapeutic modalities. Analyses of
genetic abnormalities or characteristic markers in
blood or other body fluids, such as BALF, chyle or
urine could provide less invasive methods for early
diagnosis of LAM.
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